American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone …
…, L McShane, K Miller, CK Osborne… - … of pathology & …, 2010 - meridian.allenpress.com
Purpose.—To develop a guideline to improve the accuracy of immunohistochemical (IHC)
estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the …
estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the …
Tamoxifen in the treatment of breast cancer
CK Osborne - New England Journal of Medicine, 1998 - Mass Medical Soc
Breast cancer is the most common cancer in women in the Western world. Because breast
cancer is estrogen-dependent, reducing estrogen secretion by oophorectomy, …
cancer is estrogen-dependent, reducing estrogen secretion by oophorectomy, …
Mechanisms of endocrine resistance in breast cancer
CK Osborne, R Schiff - Annual review of medicine, 2011 - annualreviews.org
The estrogen receptor (ER) pathway plays a pivotal role in breast cancer development and
progression. Endocrine therapy to block the ER pathway is highly effective, but its usefulness …
progression. Endocrine therapy to block the ER pathway is highly effective, but its usefulness …
LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
…, N Wulffraat, P Leboulch, A Lim, CS Osborne… - science, 2003 - science.org
We have previously shown correction of X-linked severe combined immunodeficiency [SCID-X1,
also known as γ chain (γc) deficiency] in 9 out of 10 patients by retrovirus-mediated γc …
also known as γ chain (γc) deficiency] in 9 out of 10 patients by retrovirus-mediated γc …
[HTML][HTML] Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early …
…, S Loibl, M Morrow, M Namer, CK Osborne… - Annals of oncology, 2013 - Elsevier
… , tenascin C promotes the aggressiveness of metastasis [41] and autocrine tenascin C is …
Kent Osborne, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, USA …
Kent Osborne, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, USA …
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy
…, J Huang, C Gutierrez, CK Osborne… - Journal of the …, 2008 - academic.oup.com
Background Tumorigenic breast cancer cells that express high levels of CD44 and low or
undetectable levels of CD24 (CD44 > /CD24 >/low ) may be resistant to chemotherapy and …
undetectable levels of CD24 (CD44 > /CD24 >/low ) may be resistant to chemotherapy and …
[PDF][PDF] Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast …
JM Harvey, GM Clark, CK Osborne, DC Allred - Journal of clinical …, 1999 - Citeseer
Purpose: Immunohistochemistry (lHC) is a newer technique for assessing the estrogen
receptor (ER) status of breast cancers, with the potential to overcome many of the shortcomings …
receptor (ER) status of breast cancers, with the potential to overcome many of the shortcomings …
[HTML][HTML] Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast …
…, P Karlsson, M Morrow, R Orecchia, CK Osborne… - Annals of oncology, 2015 - Elsevier
The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial
new evidence on locoregional and systemic therapies for early breast cancer. Further …
new evidence on locoregional and systemic therapies for early breast cancer. Further …
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on …
…, C Yoshizawa, DC Allred, CK Osborne… - The lancet …, 2010 - thelancet.com
Background The 21-gene recurrence score assay is prognostic for women with node-negative,
oestrogen-receptor-positive breast cancer treated with tamoxifen. A low recurrence score …
oestrogen-receptor-positive breast cancer treated with tamoxifen. A low recurrence score …
Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer
…, SAW Fuqua, MI Savage, CK Osborne… - Clinical Cancer …, 2015 - AACR
Purpose: Genomic profiling studies suggest that triple-negative breast cancer (TNBC) is a
heterogeneous disease. In this study, we sought to define TNBC subtypes and identify subtype…
heterogeneous disease. In this study, we sought to define TNBC subtypes and identify subtype…